RA Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

RA Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,000,000	Closed	-$31.8M	–	58
2014 Q4	$31.8M	Sell	1,000,000 -4,250,000	-81%	-$121M	3.41%	9
2014 Q3	$130M	Hold	5,250,000	–	–	15.36%	1
2014 Q2	$119M	Hold	5,250,000	–	–	11.99%	2
2014 Q1	$128M	Hold	5,250,000	–	–	9.16%	2
2013 Q4	$131M	Hold	5,250,000	–	–	15.28%	1
2013 Q3	$144M	Buy	5,250,000 +250,000	+5%	+$5.23M	15.05%	1
2013 Q2	$90.8M	Buy	+5,000,000	New	+$68.9M	12.04%	2

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RA Capital Management's ACAD Position: Q3 2015 in Review

RA Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2015, closing a stake of 27,300 shares — an estimated $1.14M sold.

RA Capital Management first reported a position in ACAD in Q2 2013 and held it in 8 quarters. The position peaked at $119M in Q2 2013. 188 funds tracked by Wall St. Rank hold ACAD as of Q3 2015.

RA Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
RA Capital Management sold 27,300 Acadia Pharmaceuticals shares in Q3 2015, an estimated $1.14M.
RA Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 8 quarters.
RA Capital Management's Acadia Pharmaceuticals position peaked at $119M in Q2 2013.
188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2015.

Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.